Gary L Schieven
Overview
Explore the profile of Gary L Schieven including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
1116
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Prabagar M, McQueney M, Bommireddy V, Siegel R, Schieven G, Lu K, et al.
Cancer Res
. 2024 Dec;
PMID: 39700406
Bacillus Calmette-Guerin (BCG) is the current standard of care for non-muscle invasive bladder cancer (NMIBC), but recurrence is common. Additional therapeutic options are a major unmet medical need for treating...
2.
He L, Zhang M, Cox M, Zhang Q, Donnell A, Zhang Y, et al.
ACS Med Chem Lett
. 2024 Feb;
15(2):189-196.
PMID: 38352849
Small molecule toll-like receptor (TLR) 7 agonists have gathered considerable interest as promising therapeutic agents for applications in cancer immunotherapy. Herein, we describe the development and optimization of a series...
3.
Poudel Y, He L, Cox M, Zhang Q, Johnson W, Cong Q, et al.
ACS Med Chem Lett
. 2024 Feb;
15(2):181-188.
PMID: 38352830
We have designed and developed novel and selective TLR7 agonists that exhibited potent receptor activity in a cell-based reporter assay. , these agonists significantly induced secretion of cytokines IL-6, IL-1β,...
4.
Sreekantha R, Mussari C, Dodd D, Pasunoori L, Hegde S, Posy S, et al.
ACS Med Chem Lett
. 2022 May;
13(5):812-818.
PMID: 35586440
The toll-like receptors (TLRs) play key roles in activation of the innate immune system. Aberrant activation of TLR7 and TLR8 pathways can occur in the context of autoimmune disorders due...
5.
Cherney E, Zhang L, Lo J, Huynh T, Wei D, Ahuja V, et al.
J Med Chem
. 2022 Feb;
65(4):3518-3538.
PMID: 35108011
The identification of agonists of the stimulator of interferon genes (STING) pathway has been an area of intense research due to their potential to enhance innate immune response and tumor...
6.
Mussari C, Dodd D, Sreekantha R, Pasunoori L, Wan H, Posy S, et al.
ACS Med Chem Lett
. 2020 Sep;
11(9):1751-1758.
PMID: 32944143
The toll-like receptor (TLR) family is an evolutionarily conserved component of the innate immune system, responsible for the early detection of foreign or endogenous threat signals. In the context of...
7.
Spergel S, Mertzman M, Kempson J, Guo J, Stachura S, Haque L, et al.
ACS Med Chem Lett
. 2019 Mar;
10(3):306-311.
PMID: 30891131
The four members of the Janus family of nonreceptor tyrosine kinases play a significant role in immune function. The JAK family kinase inhibitor, tofacitinib , has been approved in the...
8.
Martyanov V, Kim G, Hayes W, Du S, Ganguly B, Sy O, et al.
PLoS One
. 2017 Nov;
12(11):e0187580.
PMID: 29121645
Background: There are no effective treatments or validated clinical response markers in systemic sclerosis (SSc). We assessed imaging biomarkers and performed gene expression profiling in a single-arm open-label clinical trial...
9.
Liu Q, Shi Q, Marcoux D, Batt D, Cornelius L, Qin L, et al.
J Med Chem
. 2017 May;
60(12):5193-5208.
PMID: 28541707
PI3Kδ plays an important role controlling immune cell function and has therefore been identified as a potential target for the treatment of immunological disorders. This article highlights our work toward...
10.
Hynes Jr J, Wu H, Kempson J, Duan J, Lu Z, Jiang B, et al.
Bioorg Med Chem Lett
. 2017 May;
27(14):3101-3106.
PMID: 28539220
A series of potent dual JAK1/3 inhibitors have been developed from a moderately selective JAK3 inhibitor. Substitution at the C6 position of the pyrrolopyridazine core with aryl groups provided exceptional...